Skip to content

Study · Randomized controlled trial · 2026

9 results

Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA.

Falcon B, Xie CC, Redline S, Grunstein R, Turnbull CD, Rapoport DM, Wang H, Chakladar S, Dimitriadis GK, Lau E, Bednarik J, Liao B, Malhotra A

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine31 Aug 2026

PMID42675225 (opens in a new tab)PMCIDPMC13530102 (opens in a new tab)DOI10.1007/s44470-026-00162-z (opens in a new tab)PepBankPUB-42675225
Download PDFPubMedAsk about this study
Jump to 9 results

Summary

PurposeObstructive sleep apnea (OSA) is a common disorder characterized by repetitive collapse of the upper airway during sleep. Given that excess adiposity is a known risk factor for OSA, we aimed to descriptively assess the association of tirzepatide, a GIP/GLP-1 receptor agonist, with changes in AHI, hypoxic burden, body weight, and blood pressure in different patient populations based on baseline characteristics such as age, sex, BMI, AHI, and neck circumference.MethodsThese post hoc analyses examined data from two Phase 3 randomized, double-blind studies evaluating maximum tolerated dose (MTD) tirzepatide (10 mg or 15 mg) compared with placebo in adults with moderate-to-severe OSA (AHI ≥ 15 events/h) and obesity (BMI ≥ 30 kg/m2) over a 52-week period. Baseline subgroup analyses were conducted in participants with non-missing relevant baseline measurements.ResultsGenerally, participants treated with tirzepatide showed greater improvements in OSA outcomes compared with placebo, regardless of baseline subgroup. Participants treated with tirzepatide experienced reductions in AHI across subgroups, regardless of baseline age (-27.7 to -34.1 events/h), sex (-19.8 to -32.6 events/h), AHI severity (-12.1 to -52.2 events/h), BMI (-25.2 to -34.4 events/h), and neck circumference (-23.9 to -30.8 events/h). Additionally, improvements were observed in body weight, systolic blood pressure, and sleep apnea-specific hypoxic burden across baseline subgroups. Overall, most participants experienced an improvement in AHI severity category with tirzepatide treatment (68% to 79%), while the majority in the placebo group saw no clinically relevant change (64% to 70%).ConclusionsIn these descriptive, hypothesis-generating, post hoc analyses, tirzepatide treatment was associated with improvements in multiple measures in participants with moderate-to-severe OSA and obesity. These improvements were observed across both studies, regardless of baseline age, sex, AHI severity, BMI, or neck circumference.Clinical trial registrationSURMOUNT-OSA program (NCT05412004).Current knowledge/study rationaleTirzepatide has been associated with clinically relevant improvements in OSA-related measures, body weight, and systolic blood pressure among individuals with moderate-to-severe OSA and obesity. These post hoc analyses aimed to assess whether there were variations in improvements based on baseline age, sex, AHI severity, BMI, or neck circumference.Study impactIn general, tirzepatide treatment was associated with improvement in OSA outcomes across both studies, regardless of baseline age, sex, AHI severity, BMI, or neck circumference, with some observed differences among some baseline characteristics. This research may help us better understand the relationship between baseline characteristics and different OSA treatment responses and may stimulate future studies in this area.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with moderate-to-severe OSA and obesity, tirzepatide reduced AHI across baseline age subgroups, by 27.7 to 34.1 events/h.

    In plain wordsIn adults with sleep apnea and obesity, tirzepatide lowered the number of breathing pauses per hour in every age group.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAHI change by baseline age subgroup
    Study

    n: not reported in source

    Outcome group
    Sleep · Sleep
    Studied dose
    10 mg or 15 mg (maximum tolerated dose) · 52 weeksAs given in this study (human).

    Measurements

    AHI change
    −34.1 to −27.7 events/h
    tirzepatide, age subgroups

    Source sentences

    Summary
    regardless of baseline age (-27.7 to -34.1 events/h)
    1 context sentence
    Summary · context
    These post hoc analyses examined data from two Phase 3 randomized, double-blind studies evaluating maximum tolerated dose (MTD) tirzepatide (10 mg or 15 mg) compared with placebo in adults with moderate-to-severe OSA (AHI ≥ 15 events/h) and obesity (BMI ≥ 30 kg/m2) over a 52-week period.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with moderate-to-severe OSA and obesity, tirzepatide reduced AHI in both sexes, by 19.8 to 32.6 events/h.

    In plain wordsIn adults with sleep apnea and obesity, tirzepatide lowered the number of breathing pauses per hour in both men and women.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAHI change by sex subgroup
    Study

    n: not reported in source

    Outcome group
    Sleep · Sleep
    Studied dose
    10 mg or 15 mg (maximum tolerated dose) · 52 weeksAs given in this study (human).

    Measurements

    AHI change
    −32.6 to −19.8 events/h
    tirzepatide, sex subgroups

    Source sentences

    Summary
    sex (-19.8 to -32.6 events/h)
    1 context sentence
    Summary · context
    These post hoc analyses examined data from two Phase 3 randomized, double-blind studies evaluating maximum tolerated dose (MTD) tirzepatide (10 mg or 15 mg) compared with placebo in adults with moderate-to-severe OSA (AHI ≥ 15 events/h) and obesity (BMI ≥ 30 kg/m2) over a 52-week period.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with moderate-to-severe OSA and obesity, tirzepatide reduced AHI across baseline AHI severity subgroups, by 12.1 to 52.2 events/h.

    In plain wordsIn adults with sleep apnea and obesity, tirzepatide lowered breathing pauses per hour at every starting severity level.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAHI change by baseline AHI severity subgroup
    Study

    n: not reported in source

    Outcome group
    Sleep · Sleep
    Studied dose
    10 mg or 15 mg (maximum tolerated dose) · 52 weeksAs given in this study (human).

    Measurements

    AHI change
    −52.2 to −12.1 events/h
    tirzepatide, AHI severity subgroups

    Source sentences

    Summary
    AHI severity (-12.1 to -52.2 events/h)
    1 context sentence
    Summary · context
    These post hoc analyses examined data from two Phase 3 randomized, double-blind studies evaluating maximum tolerated dose (MTD) tirzepatide (10 mg or 15 mg) compared with placebo in adults with moderate-to-severe OSA (AHI ≥ 15 events/h) and obesity (BMI ≥ 30 kg/m2) over a 52-week period.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with moderate-to-severe OSA and obesity, tirzepatide reduced AHI across baseline BMI subgroups, by 25.2 to 34.4 events/h.

    In plain wordsIn adults with sleep apnea and obesity, tirzepatide lowered breathing pauses per hour at every starting body mass index.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAHI change by baseline BMI subgroup
    Study

    n: not reported in source

    Outcome group
    Sleep · Sleep
    Studied dose
    10 mg or 15 mg (maximum tolerated dose) · 52 weeksAs given in this study (human).

    Measurements

    AHI change
    −34.4 to −25.2 events/h
    tirzepatide, BMI subgroups

    Source sentences

    Summary
    BMI (-25.2 to -34.4 events/h)
    1 context sentence
    Summary · context
    These post hoc analyses examined data from two Phase 3 randomized, double-blind studies evaluating maximum tolerated dose (MTD) tirzepatide (10 mg or 15 mg) compared with placebo in adults with moderate-to-severe OSA (AHI ≥ 15 events/h) and obesity (BMI ≥ 30 kg/m2) over a 52-week period.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with moderate-to-severe OSA and obesity, tirzepatide reduced AHI across baseline neck circumference subgroups, by 23.9 to 30.8 events/h.

    In plain wordsIn adults with sleep apnea and obesity, tirzepatide lowered breathing pauses per hour at every starting neck size.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAHI change by baseline neck circumference subgroup
    Study

    n: not reported in source

    Outcome group
    Sleep · Sleep
    Studied dose
    10 mg or 15 mg (maximum tolerated dose) · 52 weeksAs given in this study (human).

    Measurements

    AHI change
    −30.8 to −23.9 events/h
    tirzepatide, neck circumference subgroups

    Source sentences

    Summary
    neck circumference (-23.9 to -30.8 events/h)
    1 context sentence
    Summary · context
    These post hoc analyses examined data from two Phase 3 randomized, double-blind studies evaluating maximum tolerated dose (MTD) tirzepatide (10 mg or 15 mg) compared with placebo in adults with moderate-to-severe OSA (AHI ≥ 15 events/h) and obesity (BMI ≥ 30 kg/m2) over a 52-week period.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with moderate-to-severe OSA and obesity, body weight improved with tirzepatide across baseline subgroups.

    In plain wordsIn adults with sleep apnea and obesity, body weight improved on tirzepatide in all the baseline subgroups.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight improvement across baseline subgroups
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 mg or 15 mg (maximum tolerated dose) · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Additionally, improvements were observed in body weight, systolic blood pressure, and sleep apnea-specific hypoxic burden across baseline subgroups.
    2 context sentences
    Summary · context
    Generally, participants treated with tirzepatide showed greater improvements in OSA outcomes compared with placebo, regardless of baseline subgroup.
    Summary · context
    These post hoc analyses examined data from two Phase 3 randomized, double-blind studies evaluating maximum tolerated dose (MTD) tirzepatide (10 mg or 15 mg) compared with placebo in adults with moderate-to-severe OSA (AHI ≥ 15 events/h) and obesity (BMI ≥ 30 kg/m2) over a 52-week period.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with moderate-to-severe OSA and obesity, systolic blood pressure improved with tirzepatide across baseline subgroups.

    In plain wordsIn adults with sleep apnea and obesity, systolic blood pressure improved on tirzepatide in all the baseline subgroups.

    Peptide
    Tirzepatide
    Outcome
    DecreaseSystolic blood pressure improvement across baseline subgroups
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    10 mg or 15 mg (maximum tolerated dose) · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Additionally, improvements were observed in body weight, systolic blood pressure, and sleep apnea-specific hypoxic burden across baseline subgroups.
    2 context sentences
    Summary · context
    Generally, participants treated with tirzepatide showed greater improvements in OSA outcomes compared with placebo, regardless of baseline subgroup.
    Summary · context
    These post hoc analyses examined data from two Phase 3 randomized, double-blind studies evaluating maximum tolerated dose (MTD) tirzepatide (10 mg or 15 mg) compared with placebo in adults with moderate-to-severe OSA (AHI ≥ 15 events/h) and obesity (BMI ≥ 30 kg/m2) over a 52-week period.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with moderate-to-severe OSA and obesity, sleep apnea-specific hypoxic burden improved with tirzepatide across baseline subgroups.

    In plain wordsIn adults with sleep apnea and obesity, low-oxygen time during sleep improved on tirzepatide in all the baseline subgroups.

    Peptide
    Tirzepatide
    Outcome
    DecreaseSleep apnea-specific hypoxic burden improvement across baseline subgroups
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sleep · Sleep
    Studied dose
    10 mg or 15 mg (maximum tolerated dose) · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Additionally, improvements were observed in body weight, systolic blood pressure, and sleep apnea-specific hypoxic burden across baseline subgroups.
    2 context sentences
    Summary · context
    Generally, participants treated with tirzepatide showed greater improvements in OSA outcomes compared with placebo, regardless of baseline subgroup.
    Summary · context
    These post hoc analyses examined data from two Phase 3 randomized, double-blind studies evaluating maximum tolerated dose (MTD) tirzepatide (10 mg or 15 mg) compared with placebo in adults with moderate-to-severe OSA (AHI ≥ 15 events/h) and obesity (BMI ≥ 30 kg/m2) over a 52-week period.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In adults with moderate-to-severe OSA and obesity, 68% to 79% of tirzepatide-treated participants improved by an AHI severity category, while 64% to 70% of the placebo group saw no clinically relevant change.

    In plain wordsIn adults with sleep apnea and obesity, most people on tirzepatide moved to a milder sleep apnea category, while most on placebo did not change.

    Peptide
    Tirzepatide
    Outcome
    IncreaseImprovement in AHI severity category
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sleep · Sleep
    Studied dose
    10 mg or 15 mg (maximum tolerated dose) · 52 weeksAs given in this study (human).

    Measurements

    Participants with improved AHI severity category
    68 to 79%
    tirzepatide
    Participants with no clinically relevant change
    64 to 70%
    placebo

    Source sentences

    Summary
    Overall, most participants experienced an improvement in AHI severity category with tirzepatide treatment (68% to 79%), while the majority in the placebo group saw no clinically relevant change (64% to 70%).
    1 context sentence
    Summary · context
    These post hoc analyses examined data from two Phase 3 randomized, double-blind studies evaluating maximum tolerated dose (MTD) tirzepatide (10 mg or 15 mg) compared with placebo in adults with moderate-to-severe OSA (AHI ≥ 15 events/h) and obesity (BMI ≥ 30 kg/m2) over a 52-week period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT05412004

Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

Eli Lilly and Companyn = 46921 Jun 2022 to 29 Mar 2024

Obstructive Sleep Apnea · Obesity

Trial pageClinicalTrials.govUpdated 30 Apr 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.